Business
Lucinda Crabtree joins OXB as CFO today
Lucinda Crabtree joins OXB as CFO today.
About this update from Oxford Biomedica Plc
[{"type":"text","content":"\n\n \n \n \nLucinda Crabtree joins Oxford Biomedica as Chief Financial Officer today\nOxford, UK - 2 September 2024: Oxford Biomedica plc (LSE:OXB) (\"Oxford Biomedica\", \"OXB\" or \"the Company\"), a quality and innovation-led cell and gene therapy CDMO, announces that Lucinda (Lucy) Crabtree Ph.D. has today joined Oxford Biomedica as Chief Financial Officer (CFO) and board member. Lucinda's appointment was previously announced on 17 July 2024.\nLucinda Crabtree was previously at MorphoSys AG where she served as CFO, leading a finance team across the US and Germany until the company's acquisition by Novartis. Previously, she was CFO at Autolus Therapeutics, a Nasdaq listed clinical stage biopharmaceutical company. Lucinda also brings extensive experience from the investment and banking sectors, having held roles at institutions including Woodford Investment Management, Goldman Sachs, and Jefferies.\n \nDr. Frank Mathias, Chief Executive Officer of Oxford Biomedica, commented: \"We are thrilled that Lucy has joined Oxford Biomedica as our new CFO and Board member today. Lucy brings a wealth of experience from her roles as a CFO and time as a healthcare investor and equity research analyst. Her experience will be invaluable as we grow our international position as a leading cell and gene therapy CDMO.\"\n \nLucinda Crabtree, Chief Financial Officer of Oxford Biomedica said: \"I am excited to be joining Oxford Biomedica as CFO today. I firmly believe in the Company's growth strategy and am looking forward to working with the Board and the rest of the leadership team. Together, I'm confident we will fulfil our mission of enabling our growing client base to deliver life-changing therapies to patients.\"\n \n-Ends-\n \nEnquiries: \n \nOxford Biomedica plc:\nSophia Bolhassan, Head of Investor Relations - T: +44 (0) 1865 509 737 / E: [email protected]\n \nICR Consilium:\nT: +44 (0)20 3709 5700 / E: [email protected]\nMary-Jane Elliott / Angela Gray / Davide Salvi\n \n \nAbout Oxford Biomedica\n \nOxford Biomedica (LSE: OXB) is a quality and innovation-led contract development and manufacturing organisation (CDMO) in cell and gene therapy with a mission to enable its clients to deliver life changing therapies to pati...